{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:15:35Z","timestamp":1762157735139,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ejphar.2016.06.011","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T07:09:33Z","timestamp":1465283373000},"page":"246-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents"],"prefix":"10.1016","volume":"786","author":[{"given":"Yuko","family":"Honda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Kamisato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2016.06.011_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2016.06.011_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jvs.2005.04.027","article-title":"Clopidogrel has no effect on d-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty","volume":"42","author":"Cassar","year":"2005","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.ejphar.2016.06.011_bib3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1160\/TH13-11-0918","article-title":"New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions","volume":"111","author":"Chan","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2016.06.011_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood.V54.3.659.659","article-title":"The effect of aggregation and release on platelet prothrombin-converting activity","volume":"54","author":"Cox","year":"1979","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2016.06.011_bib5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.ejphar.2016.06.011_bib6","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/S0049-3848(14)50024-2","article-title":"Insights into platelet-based control of coagulation","volume":"133","author":"de Witt","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2016.06.011_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tcm.2014.10.017","article-title":"Non-vitamin K oral anticoagulants in atrial fibrillation: where are we now?","volume":"25","author":"Dzeshka","year":"2015","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2016.06.011_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HCO.0000000000000024","article-title":"Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation: the clinical dilemma of triple therapy","volume":"29","author":"Fitchett","year":"2014","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.ejphar.2016.06.011_bib9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.thromres.2014.03.009","article-title":"Safety and efficacy of edoxaban in patients undergoing hip fracture surgery","volume":"133","author":"Fuji","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2016.06.011_bib10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial","volume":"134","author":"Fuji","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2016.06.011_bib11","first-page":"27","article-title":"Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb","volume":"13","author":"Fuji","year":"2015","journal-title":"J"},{"key":"10.1016\/j.ejphar.2016.06.011_bib12","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1160\/TH11-07-0451","article-title":"Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates","volume":"106","author":"Fukuda","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2016.06.011_bib13","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2016.06.011_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejphar.2012.04.031","article-title":"Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats","volume":"686","author":"Furugohri","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2016.06.011_bib15","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2016.06.011_bib16","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai.-V.T.E. Investigators","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2016.06.011_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2016.06.011_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.2515","article-title":"Arterial thrombosis--insidious, unpredictable and deadly","volume":"17","author":"Jackson","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2016.06.011_bib19","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":"Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"27","author":"Jernberg","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2016.06.011_bib20","doi-asserted-by":"crossref","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2016.06.011_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/ph5030279","article-title":"Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study","volume":"5","author":"Kubitza","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2016.06.011_bib22","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2016.06.011_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2016.06.011_bib24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1160\/TH04-09-0597","article-title":"Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk","volume":"93","author":"van der Meijden","year":"2005","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2016.06.011_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/FJC.0b013e3182970991","article-title":"The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor","volume":"62","author":"Mendell","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2016.06.011_bib26","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1055\/s-0038-1665413","article-title":"Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants","volume":"78","author":"Morishima","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2016.06.011_bib27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.thromres.2012.05.008","article-title":"Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats","volume":"130","author":"Morishima","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2016.06.011_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.thromres.2013.05.020","article-title":"Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats","volume":"132","author":"Morishima","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2016.06.011_bib29","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2016.06.011_bib30","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2016.06.011_bib31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1160\/TH06-08-0451","article-title":"Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease","volume":"96","author":"Rao","year":"2006","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2016.06.011_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.vascn.2009.11.002","article-title":"Optimization of ferric chloride induced thrombosis model in rats: effect of anti-platelet and anti-coagulant drugs","volume":"61","author":"Surin","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejphar.2016.06.011_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0049-3848(03)00339-6","article-title":"Anti-thrombotic activity of PDR, a newly synthesized L-Arg derivative, on three thrombosis models in rats","volume":"110","author":"Tang","year":"2003","journal-title":"Thromb. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0014299916303703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0014299916303703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T19:49:19Z","timestamp":1692388159000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299916303703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":33,"alternative-id":["S0014299916303703"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.06.011","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.ejphar.2016.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}